An Experimental Duchenne Muscular Dystrophy Gene Therapy Has Been Taken Off Clinical Hold

A Phase I/II clinical trial of the investigational gene therapy SGT-001 designed to treat Duchenne muscular dystrophy has had its clinical hold lifted by the US Food and Drug Administration…

Continue Reading An Experimental Duchenne Muscular Dystrophy Gene Therapy Has Been Taken Off Clinical Hold
ICYMI: Recruitment Has Begun For a Phase I Clinical Trial of A Drug Designed to Treat Parkinsonian Diseases
qimono / Pixabay

ICYMI: Recruitment Has Begun For a Phase I Clinical Trial of A Drug Designed to Treat Parkinsonian Diseases

Prana Biotechnology has announced that it has begun recruiting healthy volunteers for its Phase I clinical trial of the experimental drug PBT434. The drug is thought to affect processes linked…

Continue Reading ICYMI: Recruitment Has Begun For a Phase I Clinical Trial of A Drug Designed to Treat Parkinsonian Diseases
Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced
rawpixel / Pixabay

Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced

Data from a Phase II clinical trial of the experimental treatment reldesemtiv for the treatment of spinal muscular atrophy has been announced. The drug has shown positive effects in the…

Continue Reading Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced
New Expanded Access Trials For FENIB and LOTS Patients Set to Begin
DarkoStojanovic / Pixabay

New Expanded Access Trials For FENIB and LOTS Patients Set to Begin

According to a story from globenewswire.com, the corporation Retrotope recently announced the initiation of single-patient, expanded access trials of its experimental product RT001. The patients involved have familial encephalopathy with neuroserpin…

Continue Reading New Expanded Access Trials For FENIB and LOTS Patients Set to Begin
A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results
qimono / Pixabay

A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results

An experimental gene therapy designed to treat Duchenne muscular dystrophy has produced exciting preliminary results in a Phase 1/2a clinical trial. Sarepta Therapeutics, the company behind the therapy’s development, announced…

Continue Reading A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results
A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released
mohamed_hassan / Pixabay

A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released

An open-label extension of a Phase II study has shown that the experimental drug lenabasum is fairly safe and tolerable in patients who have diffuse cutaneous systemic sclerosis. The full…

Continue Reading A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released
Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica
LionFive / Pixabay

Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica

According to a story from Newswise, a team of scientists and researchers have recently completed research that managed to reveal the genetic nature of the unusual rare disease neuromyelitis optica.…

Continue Reading Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica

Interim Data From a Study of a Sickle Cell Disease Gene Therapy Has Been Announced

The experimental gene therapy LentiGlobin for the treatment of severe sickle cell disease is being investigated in an ongoing Phase 1 clinical trial. Bluebird Bio, the company developing the therapy,…

Continue Reading Interim Data From a Study of a Sickle Cell Disease Gene Therapy Has Been Announced

Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released

Clinical data from a Phase 2 study of the experimental drug X4P-001-RD for the treatment of WHIM syndrome has been announced at the European Hematology Association’s 23rdCongress in Stockholm. The…

Continue Reading Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released

Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial

According to a story from globenewswire.com, the biopharmaceutical company Idera Pharmaceuticals recently released the data from its Phase 2 trial for IMO-8400, an investigational product in development for the treatment…

Continue Reading Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial
The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment
ColiN00B / Pixabay

The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment

The first patient has undergone stem cell transplant treatment in the third cohort of a Phase I clinical study of the experimental treatment ISC-hpNSC for Parkinson’s disease. The full article can…

Continue Reading The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment
The First Patients Have Been Enrolled on a Phase 3 Clinical Trial Evaluating a Potential CRPS Treatment
rawpixel / Pixabay

The First Patients Have Been Enrolled on a Phase 3 Clinical Trial Evaluating a Potential CRPS Treatment

The first patients have been enrolled in two clinical trials of the experimental drug neridronate. The trials are part of the company’s Phase 3 program to evaluate the effects of…

Continue Reading The First Patients Have Been Enrolled on a Phase 3 Clinical Trial Evaluating a Potential CRPS Treatment
Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1
mohamed_hassan / Pixabay

Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1

A phase 1/2 study of the drug lumasiran for the treatment of primary hyperoxaluria Type 1 has produced encouraging results, reports Alnylam Pharmaceuticals. The full article can be read here,…

Continue Reading Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1
PET Scans Can Help in the Adjustment of Treatment for Esophageal Cancer, Study Says
hioahelsefag / Pixabay

PET Scans Can Help in the Adjustment of Treatment for Esophageal Cancer, Study Says

According to a story from coloradocancerblogs.org, a recent study demonstrated that data gathered from PET scans could help providers tailor their treatment more precisely in cases of esophageal cancer, resulting…

Continue Reading PET Scans Can Help in the Adjustment of Treatment for Esophageal Cancer, Study Says
Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released
jarmoluk / Pixabay

Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released

Promising data from the ongoing Phase I clinical trial Explorer has been announced by Blueprint Medicines Corporation. The trial is designed to evaluate the effects of the experimental drug avapritinib…

Continue Reading Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released